Tafluprost/timolol - Santen Pharmaceutical

Drug Profile

Tafluprost/timolol - Santen Pharmaceutical

Alternative Names: DE-111; Tafluprost/timolol maleate; TAPCOM; Taptiqom; Timolol maleate/tafluprost; Timolol/tafluprost

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santen Oy; Santen Pharmaceutical
  • Developer Asahi Glass; Santen Oy; Santen Pharmaceutical
  • Class Amino alcohols; Antiglaucomas; Antihypertensives; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 16 Mar 2018 Santen Pharmaceutical completes a clinical trial for Open angle glaucoma in Japan (Ophthalmic) (UMIN000023883)
  • 01 Dec 2016 Santen Pharmaceutical completes a phase II trial for Open angle glaucoma and Ocular hypertension in Japan (Ophthalmic) (UMIN000016052)
  • 09 Sep 2016 Launched for Ocular hypertension and Glaucoma in Estonia (Ophthalmic) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top